目的 比较新型抗凝药物阿哌沙班在非瓣膜性心房颤动患者缺血性脑卒中预防的有效性和安全性.方法 选择门]诊及住院治疗的非瓣膜性心房颤动患者45例作为治疗组,给予阿哌沙班(5 mg,2次/d)治疗;选择同期住院服用华法林的非瓣膜性心房颤动患者54例作为对照,所有患者服药3个月后进行随访,比较2组缺血性脑卒中、非中枢神经系统性栓塞事件、出血事件及不良反应的发生率.结果 与治疗组比较,对照组在各栓塞事件和总体发生率均低于华法林组,差异有统计学意义(x-2=5.0366,P=0.0248);此外治疗组在出血事件发生率也低于对照组组,差异有统计学意义(x2 =4.6200,P=0.0316).而在不良反应方面,治疗组的不良反应较轻微,与对照组比较,差异无统计学意义(P＞0.05).结论 新型口服抗凝药物阿哌沙班对非瓣膜房颤患者缺血性脑卒中预防效果优于华法林,安全性亦较好,看好其未来在临床的应用.%Objective To observe the efficiency and safety of apixaban in the prevention of ischemic stroke in patients with nonvalvular atrial fibrillation (AF) patients.Methods 45 cases with nonvalvular atrial fibrillation from inpatients and out patients were selected to be treatment group and apixaban was administrated (5 mg,twice a day) while 54 cases from inpatients treated with warfarin were selected to be control group;follow-up was performed 3 months after drug administration;a comparative study was made to the occurrence in ischemic stroke,non-central nerve system thrombosis,hemorrhage and other side effects between the 2 groups.Results The total occurrence of thrombosis and that of hemorrhage in treatment group were both lower than those in control group with statistical differences (x2=5.0366,P=0.0248;x2-=4.6200,P=0.0316) while existed no difference of statistical significance in side effects between the 2 groups (P＞0.05).Conclusions Apixaban is of better effect with superior safety on AF patients in preventing ischemic stroke than warfarin;it is worthy of wider clinical application.
展开▼
